Midas Enzalutamide Midas Enzalutamide

X

Find Enzalutamide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

Enzalutamide
Also known as: 915087-33-1, Mdv3100, Mdv-3100, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide, Mdv 3100, Enzalutamide (mdv3100)
Molecular Formula
C21H16F4N4O2S
Molecular Weight
464.4  g/mol
InChI Key
WXCXUHSOUPDCQV-UHFFFAOYSA-N
FDA UNII
93T0T9GKNU

Enzalutamide is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.
Enzalutamide is an Androgen Receptor Inhibitor. The mechanism of action of enzalutamide is as an Androgen Receptor Antagonist, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 2C19 Inducer.
1 2D Structure

Enzalutamide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
2.1.2 InChI
InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
2.1.3 InChI Key
WXCXUHSOUPDCQV-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
2.2 Other Identifiers
2.2.1 UNII
93T0T9GKNU
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-n-(methyl-d3)benzamide

2. 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-n-methyl-benzamide

3. Enzalutamide D3

4. Hc 1119

5. Hc-1119

6. Mdv 3100

7. Mdv-3100

8. Mdv3100

9. Xtandi

2.3.2 Depositor-Supplied Synonyms

1. 915087-33-1

2. Mdv3100

3. Mdv-3100

4. 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide

5. Mdv 3100

6. Enzalutamide (mdv3100)

7. Xtandi

8. Mdv3100 (enzalutamide)

9. 93t0t9gknu

10. Chebi:68534

11. 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-n-methylbenzamide

12. 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-n-methylbenzamide

13. 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluoro-n-methylbenzamide

14. Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-n-methyl-

15. Enzalutamide [usan]

16. Enzalutamide [usan:inn]

17. Unii-93t0t9gknu

18. Xtandi (tn)

19. Enzalutamide [mi]

20. Enzalutamide; Mdv3100

21. Enzalutamide (jan/usan)

22. Enzalutamide [inn]

23. Enzalutamide [jan]

24. Mdv3100, Aldrichcpr

25. Enzalutamide [vandf]

26. Mls006010067

27. Enzalutamide [who-dd]

28. Schembl189749

29. Gtpl6812

30. Chembl1082407

31. Dtxsid10912307

32. Ex-a046

33. Bcpp000169

34. Enzalutamide [orange Book]

35. Hms3654l07

36. Hms3672m13

37. Hms3744c19

38. Nc-54

39. Amy10296

40. Asp-9785

41. Bcp02361

42. Bbl102957

43. Bdbm50425732

44. Mfcd14155804

45. Nsc755605

46. Nsc766085

47. S1250

48. Stl556766

49. Zinc34806477

50. Akos015851022

51. Mdv-3100;enzalutamide;mdv 3100

52. Bcp9000901

53. Ccg-264879

54. Cs-0317

55. Db08899

56. Nsc-755605

57. Nsc-766085

58. Sb20413

59. Ncgc00263120-01

60. 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-n-methyl-benzamide

61. Ac-26924

62. As-17047

63. Benzamide,4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-n-methyl-

64. Hy-70002

65. Mdv3100, 95%

66. Smr004701227

67. Ft-0670957

68. Sw219288-1

69. A25302

70. D10218

71. Ab01565849_02

72. Sr-01000941580

73. J-519668

74. Q1996756

75. Sr-01000941580-1

76. Brd-k56851771-001-01-9

2.4 Create Date
2007-03-07
3 Chemical and Physical Properties
Molecular Weight 464.4 g/mol
Molecular Formula C21H16F4N4O2S
XLogP33.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass464.09300959 g/mol
Monoisotopic Mass464.09300959 g/mol
Topological Polar Surface Area109 Ų
Heavy Atom Count32
Formal Charge0
Complexity839
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameXtandi
PubMed HealthEnzalutamide (By mouth)
Drug ClassesAntiandrogen, Antineoplastic Agent
Drug LabelEnzalutamide is an androgen receptor inhibitor. The chemical name is 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide. The molecular weight is 464.44 and molecular formula is C21...
Active IngredientEnzalutamide
Dosage FormCapsule
RouteOral
Strength40mg
Market StatusPrescription
CompanyAstellas

2 of 2  
Drug NameXtandi
PubMed HealthEnzalutamide (By mouth)
Drug ClassesAntiandrogen, Antineoplastic Agent
Drug LabelEnzalutamide is an androgen receptor inhibitor. The chemical name is 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide. The molecular weight is 464.44 and molecular formula is C21...
Active IngredientEnzalutamide
Dosage FormCapsule
RouteOral
Strength40mg
Market StatusPrescription
CompanyAstellas

4.2 Drug Indication

Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.


FDA Label


Xtandi is indicated for:

- the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5. 1).

- the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5. 1).

- the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1).

- the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-B2/p52.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
ENZALUTAMIDE
5.2.2 FDA UNII
93T0T9GKNU
5.2.3 Pharmacological Classes
Androgen Receptor Inhibitor [EPC]; Cytochrome P450 2C19 Inducers [MoA]; Cytochrome P450 2C9 Inducers [MoA]; Cytochrome P450 3A4 Inducers [MoA]; Androgen Receptor Antagonists [MoA]
5.3 ATC Code

L02BB04


L02BB04

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


L - Antineoplastic and immunomodulating agents

L02 - Endocrine therapy

L02B - Hormone antagonists and related agents

L02BB - Anti-androgens

L02BB04 - Enzalutamide


5.4 Absorption, Distribution and Excretion

Absorption

The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Enzalutamide also accumulates. Food does not affect its absorption. Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours); Cmax, steady state, enzalutamide = 16.6 g/mL; Cmax, steady state, N-desmethyl enzalutamide = 12.7 g/mL; Time to steady state, daily dosing = 28 days;


Route of Elimination

Enzalutamide is primarily eliminated by hepatic metabolism. 71% of the dose is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).


Volume of Distribution

Apparent volume of distribution (Vd/F), single oral dose = 110 L


Clearance

Apparent clearance (CL/F), single oral dose = 0.56 L/h (range of 0.33 - 1.02 L/h)


5.5 Metabolism/Metabolites

Enzalutamide is hepatically metabolized, primarily by CYP2C8 and CYP3A4. The enzyme that converts enzalutamide to its active metabolite, N-desmethyl enzalutamide, is CYP2C8. The activity of N-desmethyl-enzalutamide is similar to that of the parent compound.


5.6 Biological Half-Life

The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.


5.7 Mechanism of Action

Enzalutamide is a competitive androgen receptor inhibitor that effects multiple stages of the signalling pathway. It is able to inhibit androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with DNA. As a result, proliferation of prostate cancer cells decreases which ultimately leads to apoptosis and decreased tumour volume.


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY